Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Belite Bio, Inc (BLTE)
USD146.78
+0.10 (+0.07%)
US NASDAQ Healthcare Biotechnology
Address
5820 Oberlin Drive 92121
San Diego, CA, US
San Diego, CA, US
CEO
Yu-Hsin Lin
Website
belitebio.com
IPO
2022-04-29
CIK 1889109 ISIN US07782B1044
Description
Belite Bio, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and advancement of novel therapies. The firm's primary therapeutic areas include atrophic age-related macular degeneration and autosomal recessive Stargardt disease. Its flagship drug candidate, LBS-008, is an investigational oral medication administered once daily. Currently undergoing Phase 3 clinical trials, LBS-008 is engineered to modulate vitamin A delivery to the eye, thus preventing the accumulation of detrimental vitamin A metabolites in ocular tissues. Furthermore, Belite Bio is advancing LBS-009, an oral anti-retinol binding protein 4 therapy, through preclinical development. This therapy targets various liver ailments, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes. Founded in 2016, Belite Bio, Inc. is headquartered in San Diego, California, and operates as a subsidiary of Lin Bioscience International Ltd.
News Sentiment (7d)
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD146.78
+0.10 (+0.07%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
186.1K
Beta
-1.24
Float Shares
18.51M
Free Float %
46.3%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.62% | -3.69% | -12.70% | -20.28% | +19.65% | -9.82% | +114.37% | +500.42% | +1,262.13% | +1,262.13% | +1,262.13% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (6 ratings, all time)
Buy
Price Targets & DCF
Current price
146.78
Low
187.00
+27.4%
Consensus
203.00
+38.3%
Median
200.00
+36.3%
High
223.00
+51.9%
DCF (Unlevered)
10.53
-92.8%
DCF (Levered)
10.51
-92.8%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 2 | 0 |
| Buy | 6 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | — | — |
| Last Quarter | 2 |
208.50
+42.0%
|
| Last Year | 9 |
189.11
+28.8%
|
| All Time | 10 |
176.20
+20.0%
|
Quality scores
Altman Z-Score
341.36
Safe zone
Piotroski F-Score
1 / 9
Weak
MOAT Score
3 / 10
No MOAT
Composite Rating
C-
Overall Score
1 / 5
Low
DCF Score
3 / 5
Medium
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%—
-
EPS growth Biotechnology: +29.7%-95.8% Q1'26: -54.5% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%—
-
EBIT margin Biotechnology: +0.0%—
-
ROIC Biotechnology: -16.1%-30.2% Q1'26: -46.9% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+9.8% Q1'26: +24.3% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.01× Q1'26: 0.00× (vs Q1'25)
Valuation Multiples
From
To
Consensus Estimates
| Metric |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 5 Rev. Ana. 5 EPS Ana. |
Dec 2027 5 Rev. Ana. 4 EPS Ana. |
Dec 2028 4 Rev. Ana. 4 EPS Ana. |
Dec 2029 3 Rev. Ana. 2 EPS Ana. |
Dec 2030 3 Rev. Ana. 2 EPS Ana. |
|---|---|---|---|---|---|---|---|
| Revenue |
—
est: 16.67M (-100.0%)
|
—
est: 16.67M (-100.0%)
|
22.50M
16.61M – 38.69M
+35.0% YoY
|
204.30M
188.97M – 219.65M
+808.0% YoY
|
512.47M
487.13M – 537.81M
+150.8% YoY
|
985.59M
727.68M – 1.69B
+92.3% YoY
|
1.41B
1.04B – 2.42B
+43.0% YoY
|
| EBITDA |
-35.67M
|
-84.21M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| EBIT |
-36.12M
|
-84.21M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| Net Income |
-36.14M
est: -39.14M (+7.7%)
|
-77.61M
est: -73.24M (-6.0%)
|
-79.43M
-142.11M – 54.56M
-8.4% YoY
|
22.42M
-162.10M – 303.06M
+128.2% YoY
|
308.15M
69.74M – 585.10M
+1,274.6% YoY
|
501.40M
330.83M – 970.39M
+62.7% YoY
|
688.62M
454.37M – 1.33B
+37.3% YoY
|
| SGA |
10.06M
|
38.83M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| EPS |
-1.18
est: -1.17 (-0.7%)
|
-2.31
est: -2.18 (-5.8%)
|
-2.21
-4.24 – 1.63
-1.2% YoY
|
0.97
-4.83 – 9.04
+143.8% YoY
|
6.88
2.08 – 17.45
+611.9% YoY
|
14.95
9.86 – 28.93
+117.2% YoY
|
20.53
13.55 – 39.74
+37.3% YoY
|
Recent Grade Changes (3M)
| Date | Firm | Previous | New Grade | Action |
|---|---|---|---|---|
| 2026-05-21 | HC Wainwright & Co. | Buy | Buy | Maintain |
| 2026-04-22 | HC Wainwright & Co. | Buy | Buy | Maintain |
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-21 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-20 | C | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-19 | C | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-18 | C | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-15 | C | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-14 | C | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-13 | C | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-12 | C | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-11 | C | 2/5 | 2/5 | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-08 | C | 2/5 | 2/5 | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-07 | C | 2/5 | 2/5 | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-06 | C | 2/5 | 2/5 | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-05 | C | 2/5 | 2/5 | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-04 | C | 2/5 | 2/5 | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-01 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-30 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-29 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-28 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-27 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-24 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-23 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-22 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-21 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-20 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-17 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-16 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
Owner's Earnings history not available.
Owner alignment
Owner's Earnings TTM
—
OE per share TTM
—
Owner's Yield
—
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
—
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
12
Total invested
124.70M
Insider transactions (90d)
18
Beneficial owners (>5%)
2
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Lin Bioscience International Ltd. | 17.10M | 58.60% | 17.10M | — | 17.10M | — | CO | Cayman Islands | 2024-02-12 | ↗ |
| 2 | Yu-Hsin Lin | 2.13M | 7.30% | 2.13M | — | 2.13M | — | IN | Australia | 2024-02-12 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
12
-56 vs prev Q
New positions
4
Closed positions
60
Increased
7
Reduced
4
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | DARWIN GLOBAL MANAGEMENT, LTD. | 3.03M +3.0M (+100.0%) | 486.92M +486.9M (+100.0%) | 9.11% +9.113 pp | 9.86% +9.858 pp | USD159.96 +0.0% | 1 qtrs NEW |
| 2 | RTW INVESTMENTS, LP | 715.3K +402.8K (+128.9%) | 114.42M +91.3M (+394.8%) | 2.15% +1.194 pp | 1.15% +0.861 pp | USD122.41 +30.7% | 2 qtrs — |
| 3 | MILLENNIUM MANAGEMENT LLC | 558.9K +538.1K (+2,594.6%) | 89.40M +87.9M (+5,724.7%) | 1.68% +1.619 pp | 0.04% +0.037 pp | USD156.77 +2.0% | 2 qtrs — |
| 4 | RA CAPITAL MANAGEMENT, L.P. | 432.5K -442.5K (-50.6%) | 69.18M +4.4M (+6.8%) | 1.30% -1.384 pp | 0.71% -0.089 pp | USD74.00 +116.2% | 2 qtrs — |
| 5 | PERCEPTIVE ADVISORS LLC | 414.2K +364.5K (+732.0%) | 66.26M +62.6M (+1,698.5%) | 1.25% +1.094 pp | 1.18% +1.075 pp | USD149.63 +6.9% | 2 qtrs — |
| 6 | EVENTIDE ASSET MANAGEMENT, LLC | 383.1K +187.8K (+96.1%) | 61.28M +46.8M (+324.0%) | 1.15% +0.554 pp | 0.96% +0.720 pp | USD116.13 +37.7% | 2 qtrs — |
| 7 | POINT72 ASSET MANAGEMENT, L.P. | 284.4K +281.3K (+9,075.4%) | 45.50M +45.3M (+19,733.7%) | 0.86% +0.847 pp | 0.05% +0.051 pp | USD158.95 +0.6% | 3 qtrs — |
| 8 | DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 233.8K +233.8K (+100.0%) | 37.40M +37.4M (+100.0%) | 0.70% +0.704 pp | 0.48% +0.478 pp | USD159.96 +0.0% | 1 qtrs NEW |
| 9 | MARSHALL WACE, LLP | 192.7K +5.2K (+2.8%) | 30.82M +16.9M (+122.2%) | 0.58% +0.005 pp | 0.03% +0.014 pp | USD75.52 +111.8% | 9 qtrs — |
| 10 | UBS GROUP AG | 128.8K +117.4K (+1,036.0%) | 20.60M +19.8M (+2,355.6%) | 0.39% +0.353 pp | 0.00% +0.003 pp | USD152.12 +5.2% | 6 qtrs — |
| 11 | BIOIMPACT CAPITAL LLC | 87.8K +87.8K (+100.0%) | 14.04M +14.0M (+100.0%) | 0.26% +0.264 pp | 1.61% +1.606 pp | USD159.96 +0.0% | 1 qtrs NEW |
| 12 | HOLOCENE ADVISORS, LP | 84.1K +84.1K (+100.0%) | 13.45M +13.4M (+100.0%) | 0.25% +0.253 pp | 0.03% +0.028 pp | USD159.96 +0.0% | 1 qtrs NEW |
| 13 | FRED ALGER MANAGEMENT, LLC | 79.4K +79.4K (+100.0%) | 12.70M +12.7M (+100.0%) | 0.24% +0.239 pp | 0.05% +0.050 pp | USD159.96 +0.0% | 1 qtrs NEW |
| 14 | WESTERN STANDARD LLC | 60.0K +60.0K (+100.0%) | 9.60M +9.6M (+100.0%) | 0.18% +0.181 pp | 4.43% +4.429 pp | USD159.96 +0.0% | 1 qtrs NEW |
| 15 | GOLDMAN SACHS GROUP INC | 44.6K +40.9K (+1,103.4%) | 7.13M +6.9M (+2,501.4%) | 0.13% +0.123 pp | 0.00% +0.001 pp | USD152.82 +4.7% | 2 qtrs — |
| 16 | SOLEUS CAPITAL MANAGEMENT, L.P. | 40.4K -169.6K (-80.8%) | 6.46M -9.1M (-58.5%) | 0.12% -0.523 pp | 0.24% -0.544 pp | USD74.00 +116.2% | 2 qtrs — |
| 17 | ADAR1 CAPITAL MANAGEMENT, LLC | 39.8K +39.8K (+100.0%) | 6.37M +6.4M (+100.0%) | 0.12% +0.120 pp | 0.47% +0.468 pp | USD159.96 +0.0% | 1 qtrs NEW |
| 18 | JANE STREET GROUP, LLC | 32.3K +32.3K (+100.0%) | 5.17M +5.2M (+100.0%) | 0.10% +0.097 pp | 0.00% +0.001 pp | USD159.96 +0.0% | 1 qtrs NEW |
| 19 | MORGAN STANLEY | 28.0K +22.8K (+435.6%) | 4.48M +4.1M (+1,057.8%) | 0.08% +0.068 pp | 0.00% +0.000 pp | USD143.66 +11.3% | 14 qtrs — |
| 20 | — | 26.0K +26.0K (+100.0%) | 4.16M +4.2M (+100.0%) | 0.08% +0.078 pp | 1.76% +1.763 pp | USD159.96 +0.0% | 1 qtrs NEW |
| 21 | QUADRATURE CAPITAL LTD | 24.8K +21.0K (+548.4%) | 3.97M +3.7M (+1,302.1%) | 0.07% +0.063 pp | 0.04% +0.037 pp | USD146.70 +9.0% | 2 qtrs — |
| 22 | SUPERSTRING CAPITAL MANAGEMENT LP | 24.7K +24.7K (+100.0%) | 3.95M +4.0M (+100.0%) | 0.07% +0.074 pp | 2.12% +2.116 pp | USD159.96 +0.0% | 1 qtrs NEW |
| 23 | AFFINITY ASSET ADVISORS, LLC | 20.0K +20.0K (+100.0%) | 3.20M +3.2M (+100.0%) | 0.06% +0.060 pp | 0.18% +0.182 pp | USD159.96 +0.0% | 1 qtrs NEW |
| 24 | PFM HEALTH SCIENCES, LP | 19.8K +19.8K (+100.0%) | 3.17M +3.2M (+100.0%) | 0.06% +0.060 pp | 0.32% +0.316 pp | USD159.96 +0.0% | 1 qtrs NEW |
| 25 | WOODLINE PARTNERS LP | 18.0K +18.0K (+100.0%) | 2.89M +2.9M (+100.0%) | 0.05% +0.054 pp | 0.01% +0.011 pp | USD159.96 +0.0% | 1 qtrs NEW |
| 26 | ARTIA GLOBAL PARTNERS LP | 18.0K +18.0K (+100.0%) | 2.88M +2.9M (+100.0%) | 0.05% +0.054 pp | 0.46% +0.459 pp | USD159.96 +0.0% | 1 qtrs NEW |
| 27 | STATE STREET CORP | 15.7K +2.5K (+18.6%) | 2.52M +1.5M (+156.3%) | 0.05% +0.007 pp | 0.00% +0.000 pp | USD55.17 +189.9% | 14 qtrs — |
| 28 | BANK OF MONTREAL /CAN/ | 15.5K +15.5K (+100.0%) | 2.50M +2.5M (+100.0%) | 0.05% +0.047 pp | 0.00% +0.001 pp | USD159.96 +0.0% | 1 qtrs NEW |
| 29 | EXOME ASSET MANAGEMENT LLC | 14.3K +14.3K (+100.0%) | 2.29M +2.3M (+100.0%) | 0.04% +0.043 pp | 1.10% +1.096 pp | USD159.96 +0.0% | 1 qtrs NEW |
| 30 | AMERIPRISE FINANCIAL INC | 13.2K +10.2K (+336.2%) | 2.11M +1.9M (+842.9%) | 0.04% +0.031 pp | 0.00% +0.000 pp | USD140.25 +14.1% | 4 qtrs — |
| 31 | BOOTHBAY FUND MANAGEMENT, LLC | 11.9K +11.9K (+100.0%) | 1.90M +1.9M (+100.0%) | 0.04% +0.036 pp | 0.03% +0.028 pp | USD159.96 +0.0% | 1 qtrs NEW |
| 32 | GEODE CAPITAL MANAGEMENT, LLC | 10.4K -5.2K (-33.2%) | 1.67M +514.5K (+44.5%) | 0.03% -0.017 pp | 0.00% +0.000 pp | USD52.80 +203.0% | 10 qtrs — |
| 33 | STEMPOINT CAPITAL LP | 9.2K +9.2K (+100.0%) | 1.47M +1.5M (+100.0%) | 0.03% +0.028 pp | 0.25% +0.251 pp | USD159.96 +0.0% | 1 qtrs NEW |
| 34 | HRT FINANCIAL LP | 8.2K +8.2K (+100.0%) | 1.31M +1.3M (+100.0%) | 0.02% +0.025 pp | 0.00% +0.004 pp | USD159.96 +0.0% | 1 qtrs NEW |
| 35 | WELLINGTON MANAGEMENT GROUP LLP | 6.2K +6.2K (+100.0%) | 991.4K +991.4K (+100.0%) | 0.02% +0.019 pp | 0.00% +0.000 pp | USD159.96 +0.0% | 1 qtrs NEW |
| 36 | CITADEL ADVISORS LLC | 5.1K -5.8K (-53.3%) | 808.6K +7.4K (+0.9%) | 0.02% -0.018 pp | 0.00% +0.000 pp | USD57.94 +176.1% | 6 qtrs — |
| 37 | BARCLAYS PLC | 4.2K +4.2K (+100.0%) | 668.0K +668.0K (+100.0%) | 0.01% +0.013 pp | 0.00% +0.000 pp | USD159.96 +0.0% | 1 qtrs NEW |
| 38 | HIGH NET WORTH ADVISORY GROUP LLC | 3.5K +— (+0.0%) | 559.9K +300.9K (+116.2%) | 0.01% 0.000 pp | 0.13% +0.067 pp | USD74.00 +116.2% | 2 qtrs — |
| 39 | Y-INTERCEPT (HONG KONG) LTD | 3.2K +3.2K (+100.0%) | 504.2K +504.2K (+100.0%) | 0.01% +0.010 pp | 0.01% +0.011 pp | USD159.96 +0.0% | 1 qtrs NEW |
| 40 | PRELUDE CAPITAL MANAGEMENT, LLC | 3.1K +3.1K (+100.0%) | 498.9K +498.9K (+100.0%) | 0.01% +0.009 pp | 0.04% +0.037 pp | USD159.96 +0.0% | 1 qtrs NEW |
| 41 | ARROWPOINT INVESTMENT PARTNERS (SINGAPORE) PTE. LTD. | 3.0K +3.0K (+100.0%) | 487.7K +487.7K (+100.0%) | 0.01% +0.009 pp | 0.07% +0.072 pp | USD159.96 +0.0% | 1 qtrs NEW |
| 42 | SG AMERICAS SECURITIES, LLC | 2.8K +2.8K (+100.0%) | 441.0K +441.0K (+100.0%) | 0.01% +0.008 pp | 0.00% +0.001 pp | USD159.96 +0.0% | 1 qtrs NEW |
| 43 | BNP PARIBAS ARBITRAGE, SNC | 2.4K -9.1K (-78.8%) | 391.6K -463.0K (-54.2%) | 0.01% -0.028 pp | 0.00% 0.000 pp | USD69.35 +130.7% | 5 qtrs — |
| 44 | YEOMANS CONSULTING GROUP, INC. | 2.4K +2.4K (+100.0%) | 383.7K +383.7K (+100.0%) | 0.01% +0.007 pp | 0.11% +0.112 pp | USD159.96 +0.0% | 1 qtrs NEW |
| 45 | CITIGROUP INC | 2.1K -1.9K (-46.7%) | 341.8K +45.1K (+15.2%) | 0.01% -0.006 pp | 0.00% +0.000 pp | USD74.00 +116.2% | 4 qtrs — |
| 46 | ROYAL BANK OF CANADA | 2.1K +2.1K (+100.0%) | 334.0K +334.0K (+100.0%) | 0.01% +0.006 pp | 0.00% +0.000 pp | USD159.96 +0.0% | 1 qtrs NEW |
| 47 | VIRTUS INVESTMENT ADVISERS, INC. | 1.9K +51.0 (+2.8%) | 301.0K +165.6K (+122.2%) | 0.01% +0.000 pp | 0.08% +0.043 pp | USD70.07 +128.3% | 4 qtrs — |
| 48 | BANK OF AMERICA CORP /DE/ | 1.9K +681.0 (+58.2%) | 296.2K +209.6K (+241.9%) | 0.01% +0.002 pp | 0.00% +0.000 pp | USD94.35 +69.5% | 10 qtrs — |
| 49 | SKOPOS LABS, INC. | 1.7K +1.7K (+100.0%) | 287.4K +287.4K (+100.0%) | 0.01% +0.005 pp | 0.01% +0.013 pp | USD159.96 +0.0% | 1 qtrs NEW |
| 50 | GAMMA INVESTING LLC | 1.8K +21.0 (+1.2%) | 284.6K +154.5K (+118.7%) | 0.01% +0.000 pp | 0.01% +0.007 pp | USD58.99 +171.2% | 9 qtrs — |
| 51 | EVERSOURCE WEALTH ADVISORS, LLC | 1.6K -108.0 (-6.3%) | 255.6K +129.4K (+102.5%) | 0.00% 0.000 pp | 0.01% +0.004 pp | USD57.70 +177.2% | 3 qtrs — |
| 52 | GSA CAPITAL PARTNERS LLP | 1.5K +1.5K (+100.0%) | 234.0K +234.0K (+100.0%) | 0.00% +0.004 pp | 0.02% +0.020 pp | USD159.96 +0.0% | 1 qtrs NEW |
| 53 | INDEPENDENT ADVISOR ALLIANCE | 1.3K +1.3K (+100.0%) | 211.0K +211.0K (+100.0%) | 0.00% +0.004 pp | 0.01% +0.005 pp | USD159.96 +0.0% | 1 qtrs NEW |
| 54 | PERSISTENT ASSET PARTNERS LTD | 673.00 +673.0 (+100.0%) | 107.7K +107.7K (+100.0%) | 0.00% +0.002 pp | 0.05% +0.048 pp | USD159.96 +0.0% | 1 qtrs NEW |
| 55 | MIRAE ASSET GLOBAL INVESTMENTS CO., LTD. | 645.00 +645.0 (+100.0%) | 103.2K +103.2K (+100.0%) | 0.00% +0.002 pp | 0.00% +0.000 pp | USD159.96 +0.0% | 1 qtrs NEW |
| 56 | CAITONG INTERNATIONAL ASSET MANAGEMENT CO., LTD | 549.00 +548.0 (+54,800.0%) | 87.8K +87.7K (+118,573.0%) | 0.00% +0.002 pp | 0.02% +0.021 pp | USD159.78 +0.1% | 4 qtrs — |
| 57 | CHINA UNIVERSAL ASSET MANAGEMENT CO., LTD. | 500.00 -4.5K (-90.0%) | 80.0K -290.0K (-78.4%) | 0.00% -0.014 pp | 0.01% -0.024 pp | USD74.00 +116.2% | 2 qtrs — |
| 58 | ADVISOR GROUP HOLDINGS, INC. | 195.00 +192.0 (+6,400.0%) | 31.2K +31.0K (+13,950.5%) | 0.00% +0.001 pp | 0.00% +0.000 pp | USD158.19 +1.1% | 9 qtrs — |
| 59 | FARTHER FINANCE ADVISORS, LLC | 101.00 +101.0 (+100.0%) | 16.2K +16.2K (+100.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD159.95 +0.0% | 1 qtrs NEW |
| 60 | WELLS FARGO & COMPANY/MN | 100.00 +100.0 (+100.0%) | 16.0K +16.0K (+100.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD159.96 +0.0% | 1 qtrs NEW |
| 61 | TD WATERHOUSE CANADA INC. | 70.00 +70.0 (+100.0%) | 11.2K +11.2K (+100.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD159.96 +0.0% | 1 qtrs NEW |
| 62 | SBI SECURITIES CO., LTD. | 50.00 -2.0 (-3.8%) | 8.0K +4.2K (+107.8%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD65.78 +143.2% | 5 qtrs — |
| 63 | ROSSBY FINANCIAL, LCC | 13.00 +— (+0.0%) | 2.1K +1.1K (+117.5%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD74.00 +116.2% | 2 qtrs — |
| 64 | JONES FINANCIAL COMPANIES LLLP | 6.00 +6.0 (+100.0%) | 960.00 +960.0 (+100.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD159.83 +0.1% | 1 qtrs NEW |
| 65 | JPMORGAN CHASE & CO | 3.00 -9.8K (-100.0%) | 480.00 -725.4K (-99.9%) | 0.00% -0.030 pp | 0.00% +0.000 pp | USD61.33 +160.8% | 9 qtrs — |
| 66 | AQUATIC CAPITAL MANAGEMENT LLC | — -41.0 (-100.0%) | — -3.0K (-100.0%) | 0.00% 0.000 pp | 0.00% 0.000 pp | USD— | 2 qtrs SOLD |
| 67 | VESTAL POINT CAPITAL, LP | — -312.5K (-100.0%) | — -23.1M (-100.0%) | 0.00% -0.959 pp | 0.00% -1.044 pp | USD— | 2 qtrs SOLD |
| 68 | RENAISSANCE TECHNOLOGIES LLC | — -2.8K (-100.0%) | — -208.1K (-100.0%) | 0.00% -0.009 pp | 0.00% 0.000 pp | USD— | 3 qtrs SOLD |
| 69 | POLYMER CAPITAL MANAGEMENT (HK) LTD | — -7.3K (-100.0%) | — -537.7K (-100.0%) | 0.00% -0.022 pp | 0.00% -0.074 pp | USD— | 2 qtrs SOLD |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 8 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Virtus Biotech Clinical Trials ETF BBC | 0.67% | 383.1K | 0.65% |
| 2 | Even Herd Long Short ETF EHLS | 0.33% | 198.0K | 2.62% |
| 3 | State Street SPDR S&P China ETF GXC | 0.10% | 460.2K | 0.59% |
| 4 | T. Rowe Price Innovation Leaders ETF TNXT | 0.09% | 15.6K | 0.49% |
| 5 | ActivePassive International Equity ETF APIE | 0.06% | 540.0K | 0.45% |
| 6 | KraneShares ICBCCS S&P China 500 Index UCITS ETF CHIN.L | 0.05% | 36.9K | 0.55% |
| 7 | State Street SPDR Portfolio Emerging Markets ETF SPEM | 0.01% | 1.85M | 0.07% |
| 8 | Fidelity Nasdaq Composite Index ETF ONEQ | 0.01% | 558.5K | 0.21% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.03
Bearish
Ratio by volume
0.90
Neutral
Buys
3
Sells
112
Shares acquired
30.0K
Shares disposed
33.2K
Cash buys
—
Cash sales
112.00
Net activity
-3,166
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-05-07 | MATA NATHAN L. | Officer | S-Sale | D | American depositary share | 226 | 152.45 | 34.5K | 440 | D | ↗ |
| 2026-05-06 | MATA NATHAN L. | Officer | S-Sale | D | American depositary share | 128 | 153.42 | 19.6K | 1,106 | D | ↗ |
| 2026-05-05 | MATA NATHAN L. | Officer | S-Sale | D | American depositary share | 120 | 153.92 | 18.5K | 2,546 | D | ↗ |
| 2026-05-04 | MATA NATHAN L. | Officer | S-Sale | D | American depositary share | 325 | 155.21 | 50.4K | 3,073 | D | ↗ |
| 2026-05-01 | MATA NATHAN L. | Officer | S-Sale | D | American depositary share | 52 | 153.89 | 8.0K | 4,614 | D | ↗ |
| 2026-04-30 | MATA NATHAN L. | Officer | S-Sale | D | American depositary share | 42 | 155.68 | 6.5K | 5,624 | D | ↗ |
| 2026-04-29 | MATA NATHAN L. | Officer | S-Sale | D | American depositary share | 339 | 156.43 | 53.0K | 5,790 | D | ↗ |
| 2026-04-28 | MATA NATHAN L. | Officer | S-Sale | D | American depositary share | 62 | 158.71 | 9.8K | 7,309 | D | ↗ |
| 2026-04-27 | MATA NATHAN L. | Officer | S-Sale | D | American depositary share | 44 | 160.83 | 7.1K | 8,622 | D | ↗ |
| 2026-04-24 | MATA NATHAN L. | Officer | S-Sale | D | American depositary share | 330 | 160.40 | 52.9K | 8,697 | D | ↗ |
| 2026-04-23 | MATA NATHAN L. | Officer | S-Sale | D | American depositary share | 267 | 164.47 | 43.9K | 10,399 | D | ↗ |
| 2026-04-22 | MATA NATHAN L. | Officer | S-Sale | D | American depositary share | 21 | 173.04 | 3.6K | 10,666 | D | ↗ |
| 2026-04-21 | Scholl Hendrik Peter | Officer | J-Other | A | Stock Option (right to buy) | 10,000 | 77.40 | 774.0K | 10,000 | I | ↗ |
| 2026-04-21 | MATA NATHAN L. | Officer | S-Sale | D | American depositary share | 78 | 164.60 | 12.8K | 12,524 | D | ↗ |
| 2026-04-21 | Lin Yu-Hsin | Director / Officer | J-Other | A | Ordinary Share | 10,000 | 0.00 | — | 182,949 | D | ↗ |
| 2026-04-21 | Chuang Hao-Yuan | Director / Officer | J-Other | A | Ordinary Share | 10,000 | 0.00 | — | 205,264 | D | ↗ |
| 2026-04-20 | MATA NATHAN L. | Officer | S-Sale | D | American depositary share | 284 | 162.76 | 46.2K | 13,382 | D | ↗ |
| 2026-04-17 | MATA NATHAN L. | Officer | S-Sale | D | American depositary share | 216 | 162.48 | 35.1K | 13,866 | D | ↗ |
| 2026-04-16 | MATA NATHAN L. | Officer | S-Sale | D | American depositary share | 216 | 158.28 | 34.2K | 15,450 | D | ↗ |
| 2026-04-15 | MATA NATHAN L. | Officer | S-Sale | D | American depositary share | 68 | 169.15 | 11.5K | 15,678 | D | ↗ |
| 2026-04-09 | Lin Yu-Hsin | Director / Officer | S-Sale | D | American depositary share | 200 | 183.00 | 36.6K | 170,934 | D | ↗ |
| 2026-04-09 | Chuang Hao-Yuan | Director / Officer | S-Sale | D | American depositary share | 291 | 183.08 | 53.3K | 93,800 | D | ↗ |
| 2026-04-09 | Chen Wan-Shan | Director | S-Sale | D | American depositary share | 1,100 | 180.43 | 198.5K | 9,096 | D | ↗ |
| 2026-03-31 | MATA NATHAN L. | Officer | A-Award | A | Stock Option (right to buy) | 144,868 | 6.00 | 869.2K | 267,934 | D | ↗ |
| 2026-03-31 | Lin Yu-Hsin | Director / Officer | A-Award | A | Stock Option (right to buy) | 206,954 | 0.44 | 90.8K | 413,908 | D | ↗ |
| 2026-03-31 | Chuang Hao-Yuan | Director / Officer | A-Award | A | Stock Option (right to buy) | 144,868 | 0.44 | 63.5K | 289,736 | D | ↗ |
| 2026-03-31 | Chen Wan-Shan | Director | A-Award | A | Stock Option (right to buy) | 13,796 | 0.44 | 6.1K | 13,796 | D | ↗ |
| 2026-03-18 | Scholl Hendrik Peter | Officer | — | — | Stock Option (right to buy) | 100,000 | 48.68 | 4.87M | 0 | I | ↗ |
| 2026-03-18 | Lu Ita | Director | — | — | Stock Option (right to buy) | 50,000 | 14.45 | 722.5K | 0 | D | ↗ |
| 2026-03-18 | Longo John Michael | Director | — | — | Stock Option (right to buy) | 50,000 | 6.00 | 300.0K | 0 | D | ↗ |
| 2026-03-18 | Lin Yu-Hsin | Director / Officer | — | — | Stock Option (right to buy) | 206,954 | 0.44 | 90.8K | 0 | D | ↗ |
| 2026-03-18 | Chuang Hao-Yuan | Director / Officer | — | — | Stock Option (right to buy) | 40,000 | 77.40 | 3.10M | 0 | D | ↗ |
| 2026-03-18 | Chen Xiao-Hui | Director | — | — | American depositary share | 0 | 0.00 | — | 400 | D | ↗ |
| 2026-03-18 | Chen Wan-Shan | Director | — | — | Ordinary Share | 0 | 0.00 | — | 23,463 | D | ↗ |
| 2026-03-18 | Biddle Gary Clark | Director | — | — | Stock Option (right to buy) | 50,000 | 6.00 | 300.0K | 0 | D | ↗ |
Executive team
Top executives
Shares Outstanding
39.97M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Hao-Yuan Chuang | Chief Financial Officer & Director | — | male |
| Hendrik Scholl | Chief Medical Officer | — | — |
| Nathan L. Mata | Chief Scientific Officer | — | — |
| Yu-Hsin Lin | Chairman of the Board of Directors & Chief Executive Officer | — | — |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for BLTE
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
